Brief: Sam Chun Dang Pharm Wins Exclusive Sales Rights To Supply Aflibercept Biosimilar For Treatment Of Macular Degeneration In Germany, Spain, Italy, Switzerland, Austria
20/11/2023 09:18
Sam Chun Dang Pharm Co Ltd 000250.KQ :
* SAM CHUN DANG PHARM: WINS EXCLUSIVE SALES RIGHTS TO SUPPLY
AFLIBERCEPT BIOSIMILAR FOR TREATMENT OF MACULAR DEGENERATION IN
GERMANY, SPAIN, ITALY, SWITZERLAND, AUSTRIA
Source text for Eikon: ID:
Further company coverage: 000250.KQ
Recent news on Sam Chun Dang Pharm
See all newsBrief: Sam Chun Dang Pharm Co European Medicines Agency Approves Phase I Clinical Study Plan On Oral Insulin In Germany
Brief: Sam Chun Dang Pharm Co To Buy 9.9 Billion Won Worth Of Shares In Optus Pharmaceutical
Brief: Sam Chun Dang Pharm To Divest 29.5 Billion Won Worth Of Own Shares
Brief: Sam Chun Dang Pharm To Divest 61 Billion Won Worth Of Own Shares
Brief: Sam Chun Dang Pharm Wins Exclusive Sales Rights To Supply Aflibercept Biosimilar For Treatment Of Macular Degeneration In Germany, Spain, Italy, Switzerland, Austria